Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating unresectable liver metastases of uveal melanoma

Trial Profile

Phase II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating unresectable liver metastases of uveal melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan (Primary)
  • Indications Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Feb 2019 According to a Delcath Systems media release, data from the study has been accepted for oral presentation and as a poster at the European Conference on Interventional Oncology (ECIO) annual meeting 2019.
    • 26 Sep 2018 According to a Delcath Systems media release, results from this trial were presented as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting (Sep 2018).
    • 26 Sep 2018 Results presented in the Delcath Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top